Fig. 2

Effects of CDKN2B-AS1 inhibition on the viability, cell cycle progression, ECM accumulation, and inflammation response of HG-treated HMCs. a–f HMCs were transfected with si-NC or si-CDKN2B-AS1. a The expression CDKN2B-AS1 in HMCs under HG treatment was assessed with qRT-PCR, and GADPH was selected as an internal reference. b, c The viability and cell cycle progression of HMCs under HG treatment were evaluated by CCK-8 or flow cytometry assays. d, e After HG treatment, the levels of PCNA, CyclinD1, Fibronectin, and Collagen IV in HMCs were detected by western blotting, and GADPH was selected as an internal control. f The levels of IL-6, IL-1β, and TNF-α in HMCs after HG treatment were measured by ELISA. The experiments were repeated 3 times, and data were presented as mean ± standard deviation. *P < 0.05, **P < 0.01, and ****P < 0.0001